iOrganBio, a pioneer in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin’s pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His extensive academic and entrepreneurial leadership will be key to expanding iOrganBio’s platform in neurological applications, according to the company.
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency, enabling scalable production for disease modeling, drug discovery, and cell therapy development. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type.
This appointment underscores iOrganBio’s commitment to advancing FDA-aligned New Approach Methodologies (NAMs) and accelerating the development of therapies for neurological diseases. The company is redefining how human cells are engineered and produced at scale for research and therapeutic applications. For more information, visit iOrgan.Bio or follow the company on LinkedIn.
Dr. Rubin’s addition to the Scientific Advisory Board is expected to provide strategic guidance as iOrganBio expands its platform capabilities to address complex neurological conditions. The company’s technology aims to deliver the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
